Novel E. coli Bacteriophage and Uses Thereof
AssigneeIntralytix, Inc.
InventorsAlexander SULAKVELIDZE, Gary Pasternack
Life of this patent
Estimating the term…
Abstract
The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli in various settings.
Claims10
An isolated bacteriophage substantially equivalent to ECTA-47, ECML-83, ECML-119, or ECML-122 deposited under ATCC accession No. PTA-8347, PTA-8348, PTA8351, or PTA-8352, said bacteriophage having lytic activity against E. coli strains (the “Targeted Bacteria”).
A method for the prevention of foodborne illnesses caused by E. coli strains, comprising contacting a food product or products with a microbial growth inhibiting effective amount of a bacteriophage composition comprising the isolated bacteriophages ECTA-47, ECML-83, ECML-119, or ECML-122 deposited under ATCC accession No. PTA-8347, PTA-8348, PTA8351, or PTA-8352, said bacteriophage having lytic activity against E. coli strains.
A method for the reduction of the incidence of foodborne illnesses caused by E. coli strains, comprising contacting a food product or products with a microbial growth inhibiting effective amount of a bacteriophage composition comprising the isolated bacteriophages ECTA-47, ECML-83, ECML-119, or ECML-122 deposited under ATCC accession No. PTA-8347, PTA-8348, PTA8351, or PTA-8352, said bacteriophage having lytic activity against E. coli strains.
Dependencies are inferred from the claim text.